BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase III
Zafgen (ZFGN) Completes Enrollment Of U.S. Phase III Trial Of Beloranib In Prader-Willi Syndrome 5/28/2015
XOMA (US) LLC (XOMA) Announces Phase III EYEGUARD-B Study Reaches Target Exacerbation Event 5/28/2015
Ultragenyx Pharmaceuticals (RARE) Announces First Patient Enrolled In Global Phase III Study Of Aceneuramic Acid (Sialic Acid) Extended Release In GNE Myopathy 5/28/2015
Pharmacyclics (PCYC) Release: Ibrutinib (IMBRUVICA) In Combination With Anti-PD-L1 Antibody (MEDI4736) Study Commences For Patients With Two Relapsed/Refractory Blood Cancers 5/28/2015
Johnson & Johnson (JNJ) Announced 10 New Approval Applications with $1 Billion Revenue Potential Each 5/27/2015
Pivotal Study Results Published In Journal Of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates In Patients With Metastatic Melanoma 5/27/2015
Synageva BioPharma (GEVA) Submits Kanuma (Sebelipase Alfa) Application For LAL Deficiency In Japan 5/27/2015
AbbVie (ABBV) Presents New Data For Its Investigational Hepatitis C Treatment In Japanese Patients With And Without Cirrhosis 5/27/2015
Zogenix (ZGNX) Announces New Efficacy Data From A Long-Term Study Of Low-Dose Fenfluramine For Treatment Of Dravet Syndrome 5/27/2015
Bellerophon Therapeutics (BLPH) Presents Late-Breaking Poster At The European Society of Cardiology's Heart Failure 2015/2nd World Congress On Acute Heart Failure 5/27/2015
Aegerion (AEGR)'s Lomitapide Achieves Primary Endpoint in Phase III Study for HoFH Patients 5/26/2015
AEterna Zentaris (AEZS)' Confirmatory Phase 3 Study for Macrilen In AGHD Meets European Medicines Agency's Study-Design Expectations 5/26/2015
Mast Therapeutics (MSTX) Announces Initiation Of EPIC-E Study 5/26/2015
Merck & Co. (MRK) Release: SIMPONI (golimumab) Gains Positive Opinion From Committee For Medicinal Products For Human Use (CHMP) For The Treatment Of Non-Radiographic Axial Spondyloarthritis 5/26/2015
NeoStem, Inc. Announces Dr. Merrick Ross Of MD Anderson Cancer Center As Lead Principal Investigator For Pivotal Phase III Trial For Metastatic Melanoma 5/26/2015
BioTie Therapies Corp. Announces Agreement With FDA On A Special Protocol Assessment For Tozadenant Phase 3 Study 5/26/2015
NeuroVive: Topline Result Of Phase III Study Of Ciclomulsion In Acute Myocardial Infarction Expected This Quarter 5/26/2015
Amicus Therapeutics, Inc. (FOLD)' Fabry Monotherapy Granted Accelerated Assessment By European Regulators 5/26/2015
Cardiorentis Completes Enrollment In Pivotal Phase III Clinical Trial Of Ularitide For Acute Heart Failure 5/22/2015
Analysts Question Intercept Pharma (ICPT) NASH Trial Phase III Length and Size 5/21/2015
IntelliPharmaCeutics Intends To Accelerate Its Rexista(TM) Oxycodone XR Development Program On The Basis Of Positive Feedback From The FDA 5/21/2015
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Study Demonstrates Significant Burden Of Obesity On Patients' Recovery From Acute Bacterial Skin Infections 5/20/2015
Bristol-Myers Squibb (BMY) Receives Amended FDA Breakthrough Therapy Designation For Investigational Daclatasvir-Based Hepatitis C Regimen 5/20/2015
Boehringer Ingelheim Release: New Data Show Benefit Of Tiotropium/Olodaterol Respimat From The Start Of COPD Maintenance Therapy1,2,3 5/20/2015
Boehringer Ingelheim Release: New Data Analyses On Investigational Tiotropium/Olodaterol Respimat Showed Greater Lung Function Improvement Compared To Tiotropium And Olodaterol Alone 5/20/2015
Alnylam (ALNY) Receives Orphan Drug Designation From The United States FDAFor Revusiran, An Investigational Rnai Therapeutic For The Treatment Of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) 5/20/2015
Sunovion Pharmaceuticals Inc. Announces Positive Results for Latuda(Lurasidone HCL) In First Placebo-Controlled Trial Of Patients With Major Depressive Disorder With Mixed (Subsyndromal Hypomanic) Features 5/20/2015
Novartis AG (NVS) Reports Two Positive U.S. Phase III Programs in COPD 5/20/2015
Debiopharm Announces Phase III Positive Results For Triptorelin 6-Month Formulation In The Management Of Central Precocious Puberty (CPP) 5/19/2015
vTv Therapeutics Initiates Pivotal Phase 3 Trial Evaluating Azeliragon For The Treatment Of Patients With Mild Alzheimer's Disease 5/19/2015
Cempra Pharmaceuticals, Inc. (CEMP) Presenting Additional Data From The Phase III Oral Solithromycin Study In Community Acquired Bacterial Pneumonia At The American Thoracic Society Conference 5/19/2015
Corium International, Inc. Announces Publication Of Promising Data For Needle-Free Transdermal Influenza Vaccine 5/19/2015
pSivida (PSDV) Reports Positive IOP Safety Data In Phase III Trial Of Medidur For Posterior Uveitis 5/19/2015
Janssen Pharmaceuticals, Inc. Release: U.S. FDA Approves INVEGA TRINZA, First and Only Four-Times-A-Year Treatment For Schizophrenia 5/19/2015
Analysis Of Phase II Data For Celgene (CELG)’s Investigational Oral GED-0301 In Patients With Active Crohn’s Disease Presented At Digestive Disease Week 5/19/2015
Eleven Biotherapeutics (EBIO) Stock Nosedives 80% Premarket as Eye Drug Flunks Phase III Test 5/19/2015
Janssen Enters Into A Worldwide Collaboration With Achillion (ACHN) To Combat Hepatitis C Virus 5/19/2015
XBiotech USA (XBIT) Secures Approval From Data Safety Monitoring Board To Continue Phase III Registration Study In Europe For Its Novel Cancer Immunotherapy 5/18/2015
TissueGene, Inc. Announces Special Protocol Assessment (SPA) Agreement With The FDA For Its Phase 3 Clinical Trial Of Invossa For Patients Suffering From Osteoarthritis Of The Knee 5/18/2015
Astellas Pharma US Release: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial 5/18/2015
Janssen Pharmaceuticals, Inc. Release: New Real-World Data Show Adults with Type 2 Diabetes, Including Those Taking Multiple Diabetes Medications, Achieve Blood Glucose Treatment Goals After Using INVOKANA (canagliflozin) 5/18/2015
Boehringer Ingelheim Presents New Data And Analyses Reinforcing The Safety And Efficacy Of OFEV (nintedanib) Capsules 5/18/2015
RedHill Biopharma Ltd. (RDHL)'s Investor Webcast Forum Provides Update On The RHB-105 Phase III Program And Potential H. Pylori Eradication Market 5/18/2015
Eleven Biotherapeutics (EBIO) Announces Top-Line Results From Pivotal Phase 3 Study Of EBI-005 In Patients With Moderate To Severe Dry Eye Disease 5/18/2015
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2015 Financial Results And Provides Corporate Update 5/18/2015
Celgene (CELG) Release: FDA Fast Track Designation Granted To Luspatercept For The Treatment Of Patients With Beta-Thalassemia 5/18/2015
Vertex (VRTX) Release: The New England Journal of Medicine Publishes Data From Two Phase 3 Studies Of ORKAMBITM (Lumacaftor/Ivacaftor) In People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation 5/18/2015
Daiichi Sankyo Release: MOVANTIK (naloxegol) Safety Analyses Of Opioid-Induced Constipation Patients 65 And Older With Chronic Non-Cancer Pain 5/18/2015
University of Washington Release: Results From The First New Therapeutic Trials In Primary Biliary Cirrhosis (PBC) In A Decade To Be Presented At Digestive Disease Week (DDW) 5/18/2015
AbbVie (ABBV), Bristol-Myers Squibb (BMY) Drug Delays Blood Cancer Progression 5/15/2015
Janssen Pharmaceuticals, Inc. Release: Real-World Data Presented At American Geriatrics Society Meeting Show Consistent Safety Of XARELTO In Elderly Patients 5/15/2015
Endo Pharmaceuticals (ENDP) And BioDelivery Sciences International (BDSI) Present Pivotal Data From Two Phase 3 Trials Demonstrating Safety And Efficacy Of Buprenorphine Hcl Buccal Film For The Management Of Chronic Pain 5/15/2015
Janssen Pharmaceuticals, Inc. Release: New Data On XARELTO Versus Vitamin K Antagonists In Atrial Fibrillation Patients Undergoing Catheter Ablation Presented At Heart Rhythm 2015 5/15/2015
Innocoll, Inc. (INNL) Announces First Patient Dosed In The Cogenzia COACT-1 Phase III Study For The Treatment Of Diabetic Foot Infection 5/15/2015
Angionetics Presents at the 2015 American Society Of Gene & Cell Therapy Conference On Generx Angiogenic Phase 3 Gene Therapy Program 5/15/2015
Novo Nordisk Inc. Release: New Analysis Of Data In Adults With Obesity Or Who Are Overweight With Weight-Related Comorbidities Showed Early Response To Saxenda (liraglutide [rDNA origin] injection) Predicted Greater Weight Loss 5/15/2015
Puma Biotech (PBYI) Founder Loses $250 Million on Disappointing Breast Cancer Drug Data 5/15/2015
ResMed (RMD) Heart Trial Stopped After Putting Patients at Risk 5/14/2015
Argos Therapeutics, Inc. (ARGS) Provides Update On Enrollment Progress For Ongoing Pivotal Phase III ADAPT Clinical Trial 5/14/2015
Angion Biomedica Corp. Advances BB3 Into Pivotal Phase 3 Clinical Trial In Renal Transplant Patients With Delayed Graft Function 5/14/2015
NewLink Genetics (NLNK) Plunges Premarket as Pancreatic Cancer Vaccine Still Sees 75% Mortality Rate 5/13/2015
TONIX Pharmaceuticals, Inc. (TNXP) Launches Phase III Clinical Study Of TNX-102 SL In Fibromyalgia 5/13/2015
CEL-SCI (CVM) Receives Authorization To Conduct Its Phase 3 Multikine Trial In Italy 5/13/2015
Bavarian Nordic (BAVA.CO) Announces Positive Results From Two Pivotal Clinical Studies Of IMVAMUNE Smallpox Vaccine 5/13/2015
Pain Therapeutics (PTIE) Announces Positive Top-Line Results From Human Abuse Potential Study With REMOXY 5/12/2015
Merck KGaA (MKGAF.PK), Darmstadt, Germany, Receives FDA Fast Track Designation For Evofosfamide For The Treatment Of Patients Living With Advanced Pancreatic Cancer 5/12/2015
NewLink Genetics (NLNK)' IMPRESS Phase III Pancreatic Cancer Trial With Algenpantucel-L To Continue Following Second Interim Analysis 5/12/2015
Takeda (TKPYY) Announces First Patient Enrolled In Global Phase 3 Study Of Ixazomib As Maintenance Therapy For Newly Diagnosed Multiple Myeloma 5/12/2015
Ophthotech Corporation (OPHT) Completes Patient Recruitment Of The First Phase 3 Pivotal Trial Of Fovista Anti-PDGF Therapy In Combination With Lucentis In Wet Age-Related Macular Degeneration Program 5/12/2015
Threshold Pharmaceuticals, Inc. (THLD)' Partner Merck KGaA (MKGAF.PK), Darmstadt, Germany, Receives FDA Fast Track Designation For Evofosfamide For The Treatment Of Patients Living With Advanced Pancreatic Cancer 5/12/2015
Results From Pulmonary Non-Tuberculous Mycobacteria (PNTM) Study Using Aradigm Corporation (ARDM)’s Liposomal Ciprofloxacin To Be Presented At American Thoracic Society 2015 International Conference 5/12/2015
CureMark, Launches New Phase III Trial In Expanded Population Of Children With Autism 5/11/2015
Chiasma Announces New Data For Investigational Octreotide Capsules To Be Presented At ECE 2015 5/11/2015
GenSpera Provides Corporate Update 5/11/2015
GW Pharma (GWPH) Initiates Phase 3 Pivotal Study Of Epidiolex (CBD) In Lennox-Gastaut Syndrome 5/11/2015
Lipocine Inc. (LPCN) Announces Presentation Of Additional LPCN 1021 Clinical Data At American Urological Association Annual Meeting 5/11/2015
CEL-SCI (CVM) Receives Authorization To Conduct Its Phase 3 Multikine Trial In Spain 5/11/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: Researchers Report That Long-Term Administration Of Thymosin B4 In A Diabetic Animal Model Prevents Progression Of Peripheral Neuropathy And Restores Sciatic Nerve Function 5/8/2015
RedHill Biopharma Ltd. (RDHL) To Host Investor Webcast Forum Following Completion Of RHB-105 Dosing In Phase III Study 5/7/2015
SANUWAVE, Inc. Provides An Update On The Dermapace Clinical Trial 5/7/2015
ViiV Healthcare Begins Phase III Programme With dolutegravir/rilpivirine Combination For HIV Maintenance Therapy 5/6/2015
AbbVie (ABBV) Release: Investigational Medicine Venetoclax Receives Breakthrough Therapy Designation In Relapsed Or Refractory Chronic Lymphocytic Leukemia In Previously Treated Patients With The 17p Deletion Genetic Mutation 5/6/2015
Indivior PLC Announces Positive Top-Line Results From Pivotal Phase 3 Trial Of RBP-7000 In Schizophrenia 5/5/2015
Oxford BioMedica PLC (OXB.L) Announces That A Summary Of The 12 Month And Three Year Follow Up Data From The Phase I/II Study With Prosavin Was Presented At The AANS Conference In The U.S. 5/5/2015
AbbVie (ABBV) Announces Pivotal Phase 3 Data Evaluating Efficacy And Safety Of HUMIRA (Adalimumab) In Patients With Non-Infectious Intermediate, Posterior, Or Panuveitis 5/5/2015
Tocagen Inc. Presents Updated Interim Survival Data From Ongoing Clinical Studies At American Association Of Neurological Surgeons (AANS)/Congress Of Neurological Surgeons (CNS) Section On Tumors 5/4/2015
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus XR Demonstrates Improved Pharmacokinetic Profile In African-American Transplant Recipients 5/4/2015
CytoDyn Submits Phase 3 Protocol To FDA After Agreement On Protocol Synopsis 5/4/2015
Braeburn Pharmaceutical Expands Pipeline To Include Schizophrenia With Endo Pharmaceuticals (ENDP) Deal 5/1/2015
Tesaro, Inc. (TSRO) Announces Completion Of Targeted Enrollment In Phase III NOVA Trial And Initiation Of The QUADRA Trial Of Niraparib 5/1/2015
CEL-SCI (CVM) Reports 4th Consecutive Month Of Record Patient Enrollment In 2015 For Its Phase III Head And Neck Cancer Trial 5/1/2015
Celgene (CELG) Release: Analysis Of REVLIMID (Lenalidomide) In Patients With Non-Del-5Q MDS Demonstrated Improved Health Related Quality Of Life Measures 5/1/2015
NeoStem, Inc. Announces First Patient Randomized In Pivotal Phase III Melanoma Immunotherapy Clinical Trial 4/30/2015
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Custirsen Phase 3 "ENSPIRIT Trial Update 4/30/2015
Lexicon Pharmaceuticals, Inc. (LXRX) Provides Clinical Pipeline Update And Reports 2015 First Quarter Financial Results 4/30/2015
Lipocine Inc. (LPCN) Announces Completion Of LPCN 1021, Oral Testosterone, Phase III Clinical Trial 4/30/2015
Celgene (CELG) And Acceleron Pharma Select Luspatercept To Advance To Phase 3 In Myelodysplastic Syndromes 4/30/2015
Gilead (GILD), Achillion (ACHN) Race to Grab Market Share As HCV Populations Abound 4/29/2015
AstraZeneca PLC (AZN) Release: Selumetinib Granted Orphan Drug Designation By FDA 4/29/2015
ErgoMed’s Co-Development Partner AEterna Zentaris (AEZS) Obtains Positive Recommendation From Data Safety Monitoring Board 4/29/2015
Amgen (AMGN) Announces FDA Advisory Committee Meeting To Review Repatha (Evolocumab) As A Treatment For High Cholesterol 4/29/2015
XBiotech USA (XBIT) Enrolls First Patient Under Revised Protocol For U.S. Phase III Registration Study Using Xilonix For Treatment Of Metastatic Colorectal Cancer 4/29/2015
GlaxoSmithKline (GSK)'s Shingles Vaccine 97.2% Effective 4/28/2015
CoLucid Pharma Announces Initiation Of First Phase 3 Pivotal Trial Of Lasmiditan In Migraine 4/28/2015
AEterna Zentaris (AEZS): Data Safety Monitoring Board Recommends Continuation Of Phase 3 Study Of Zoptarelin Doxorubicin In Advanced Endometrial Cancer 4/28/2015
Synthon Pharmaceuticals Announces Successful Outcomes From The Open-Label Extension Of The Phase III GATE Study Of Synthon’s Glatiramer Acetate 4/28/2015
Merck & Co. (MRK) Announces Publication Of Pivotal Data From Phase 3 Clinical Studies Of ZERBAXA (Ceftolozane/Tazobactam) In The Lancet And Clinical Infectious Diseases 4/28/2015
Aerie (AERI) Freefalls Aftermarket as Rhopressa Fails Phase III Study 4/27/2015
TetraPhase Pharmaceuticals (TTPH)'s Eravacycline Meets Primary Endpoint In Phase III Study 4/27/2015
AbbVie (ABBV) Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX + EXVIERA In Chronic Hepatitis C Patients With Renal Impairment At The International Liver Congress 2015 4/27/2015
Can-Fite BioPharma (CFBI) Reports Positive Results From Further Analysis Of Phase II/III Psoriasis Trial 4/27/2015
RedHill Biopharma Ltd. (RDHL) Announces Completion Of Patient Enrollment In A Phase III Study Of RHB-105 For H. Pylori Infection 4/27/2015
NeoStem, Inc.'s Lead Immuno-Oncology Product Candidate, NBS20, Receives ATMP Classification From The European Medicines Agency 4/27/2015
Bristol-Myers Squibb (BMY) Release: ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% Of Post-Liver Transplant Patients With Hepatitis C And Up To 94% Of Hepatitis C Patients With Cirrhosis (Child-Pugh Class A Or B) 4/27/2015
Enanta Pharmaceuticals, Inc. Announces Preliminary Data From AbbVie (ABBV)’s Phase 3b RUBY-I Study In Chronic Hepatitis C Patients With Renal Impairment Presented At The International Liver Congress 2015 4/27/2015
Otonomy, Inc. (OTIC) Presents Auripro Phase III Results At American Society Of Pediatric Otolaryngology Conference 4/27/2015
BioMarin (BMRN) Presents Data On Duchenne Muscular Dystrophy At The 67th American Academy of Neurology Annual Meeting 4/24/2015
GlaxoSmithKline (GSK)'s Malaria Vaccine Phase III Study Containing Agenus’ QS-21 Published In The Lancet 4/24/2015
GENFIT (ALGFT): New Proof Of Efficacy Of Gft505 In Nash And Positive Expert Opinion 4/24/2015
Actavis (ACT) Announces Topline Phase 3 Clinical Trial Results For Single-Dose DALVANCE (Dalbavancin) In The Treatment Of ABSSSI 4/24/2015
Aerie (AERI) Reports Initial Rhopressa Phase III Efficacy Results 4/24/2015
MedDay Reports Positive Pivotal Phase III Study Results With MD1003 In Patients With Progressive Multiple Sclerosis 4/24/2015
Astellas Pharma US Release: CRESEMBA (Isavuconazonium Sulfate) Data To Be Presented At The European Congress Of Clinical Microbiology And Infectious Diseases 4/24/2015
BioTie Therapies Corp. Provides Update On Tozadenant Phase 3 Program 4/23/2015
Merck & Co. (MRK) Announces Results From Phase 2/3 Study Of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir In Patients With Advanced Chronic Kidney Disease 4/23/2015
Medivir AB (MVRBF): Data From OPTIMIST Trials Show SVR12 Rates Of 97 Percent In HCV Patients Without Cirrhosis And 84 Percent In HCV Patients With Cirrhosis 4/23/2015
Merck & Co. (MRK) Touts Results From C-SURFER Phase II/III Clinical Trial 4/23/2015
Effect Of Genzyme (GENZ)’s Multiple Sclerosis Treatment Lemtrada (Alemtuzumab) On Slowing Brain Atrophy And MRI Lesion Activity Maintained Through Four Years 4/23/2015
Janssen Sciences Ireland UC Announces SVR12 Rates With Twelve Weeks Of Treatment With All-Oral, Once-Daily Regimen Of Simeprevir ? Plus Sofosbuvir ? In Genotype 1 HCV Patients With And Without Cirrhosis 4/23/2015
GW Pharmaceuticals (GWPH) Announces New Physician Reports Of Epidiolex Treatment Effect In Children And Young Adults With Treatment-Resistant Epilepsy 4/23/2015
Isis Pharmaceuticals, Inc. (ISIS) Reports Positive Data From ISIS-TTR Rx In Patients With TTR Amyloidosis 4/23/2015
CorMedix (CRMD) Presents Data from Neutrolin Post Marketing Surveillance Study At Two Medical Conferences 4/23/2015
Janssen Announces SVR12 Rates With Twelve Weeks Of Treatment With All-Oral, Once-Daily Regimen Of Simeprevir Plus Sofosbuvir In Genotype 1 HCV Patients With And Without Cirrhosis 4/23/2015
Pfizer (PFE)'s New Leukemia Drug Meets Hematologic Remission Endpoint in Phase III Study 4/22/2015
Eli Lilly (LLY)'s Ixekizumab Succeeds in Late-Stage Study, Meets Primary Endpoint 4/22/2015
Portage Biotech's Biohaven To Begin Phase 1 Study In 3Q2015 And Readying For Phase 3 Study Start By 1Q2016 4/22/2015
Celator Pharmaceuticals, Inc. Presents Data At AACR Annual Meeting 4/22/2015
Baxter International (BAX)'s Bleeding Disorder Drug Delivers 100% Success Rate in Late-Stage Study 4/21/2015
GW Pharmaceuticals (GWPH) Initiates Second Phase 3 Pivotal Trial For Epidiolex In Dravet Syndrome 4/21/2015
Otonomy, Inc. (OTIC) To Present Auripro Phase 3 Results At American Society Of Pediatric Otolaryngology Conference 4/21/2015
Acacia Pharma Initiates Phase 3 Combination Prophylaxis Study With APD421 In Post-Operative Nausea & Vomiting (PONV) 4/21/2015
Biogen (BIIB) Release: PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented At American Academy of Neurology Annual Meeting Support Long-Term Safety And Efficacy In Multiple Sclerosis Patients 4/21/2015
Upsher-Smith Laboratories Research On Qudexy XR (topiramate) Extended-Release Capsules Highlighted At the 2015 American Academy of Neurology Annual Meeting 4/21/2015
Enrollment In Mast Therapeutics (MSTX)' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 4/21/2015
Onconova Therapeutics Inc. (ONTX) Highlights Rigosertib And Early-Stage Programs At The 2015 AACR Annual Meeting 4/21/2015
Ampio Pharmaceuticals, Inc. (AMPE) Shares Decimated on Failed Trial Results 4/20/2015
KEYTRUDA (Pembrolizumab), Merck & Co. (MRK)’s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival And Overall Response Rate Compared To Ipilimumab An Anti-CTLA-4 Therapy 4/20/2015
Full Data On Baxter International (BAX)’s Investigational Recombinant Treatment BAX 111 Supports Potential Role To Treat Von Willebrand Disease 4/20/2015
Cyclacel Pharmaceuticals, Inc. (CYCC)'s Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential And Synergy With Other Anti-Cancer Compounds 4/20/2015
MediWound (MDWD) Initiates U.S. Phase 3 Trial With NexoBrid To Treat Severe Burns 4/20/2015
Argos Therapeutics, Inc. (ARGS) To Present Update On Pivotal Phase 3 ADAPT Clinical Trial During 2015 ASCO Annual Meeting 4/20/2015
SAGE Therapeutics Announces First Patient Treated Under Phase 3 Expanded Access Protocol To Evaluate SAGE-547 In Patients With Super-Refractory Status Epilepticus 4/20/2015
Onconova Therapeutics Inc. (ONTX) Submits Pivotal Clinical Trial Protocol For IV Rigosertib In Higher-Risk Myelodysplastic Syndromes To FDA And European Medicines Agency 4/20/2015
Data Presented At AACR Demonstrate Peregrine Pharmaceuticals, Inc. (PPHM)' Bavituximab Induces Immune Activation In PD-L1 Negative NSCLC Tumors 4/20/2015
Eli Lilly (LLY)'s Ixekizumab Met Primary Endpoint In A Phase 3 Study Investigating The Treatment Of Psoriatic Arthritis 4/20/2015
Pembrolizumab, Merck & Co. (MRK)'s Investigational Anti PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival And Overall Response Rate Compared To Ipilimumab, An Anti-CTLA-4 Therapy, In A Phase 3 Study Of Patients With Advanced Melanoma 4/20/2015
Merz Neurosciences To Present Key Clinical Data At The Annual Meeting Of The American Academy of Neurology 4/20/2015
Bio Products Laboratory, Ltd. Announces Results From Phase III Registration Study Of Its Factor X Coagulation Product 4/20/2015
Global Strategic Partners Merck KGaA (MKGAF.PK), Darmstadt, Germany, And Pfizer (PFE) nitiate Phase III Study With Avelumab* In Patients With Stage IIIb/IV Non-Small Cell Lung Cancer 4/20/2015
Investors Suddenly Interested in Synta (SNTA) and Its Upcoming Cancer Data 4/17/2015
Ipsen (IPN.PA), Active Biotech AB (BTPC) Plummet As Prostate Cancer Drug Flunks Late-Stage Trial 4/17/2015
H. Lundbeck A/S (LUN.CO) and Otsuka America Pharmaceutical, Inc. Release: Results Of Phase III Study Of Brexpiprazole In Adult Patients With Schizophrenia Published In American Journal Of Psychiatry 4/17/2015
MedDay Announces Its Pivotal Phase III Study Of MD1003 In Patients With Progressive Multiple Sclerosis Meets Primary Endpoint 4/17/2015
Full Data On Baxter International (BAX)’s Investigational Recombinant Treatment BAX 111 Supports Potential Role To Treat Von Willebrand Disease 4/17/2015
Bristol-Myers Squibb (BMY) Soars After Halting Study Early As Opdivo Aces Test Again 4/17/2015
Pfizer (PFE) Beams As Cancer Drug Efficacy Stops Trial Early and Analysts Predict Game Changer 4/17/2015
Galena Biopharma  (GALE) Completes Over-Enrollment Of Neuvax (Nelipepimut-S) Phase 3 PRESENT Clinical Trial 4/16/2015
ZS Pharma (ZSPH) Announces Publications In Peer-Reviewed Medical Journals 4/16/2015
Peregrine Pharmaceuticals, Inc. (PPHM) Announces Three Abstracts Accepted For Presentation At American Association for Cancer Research 2015 Annual Meeting 4/16/2015
AEterna Zentaris (AEZS) Files Additional Patent Application To Strengthen IP Protection Of Zoptarelin Doxorubicin 4/16/2015
Adamis (ADMP) Pharmaceuticals Announces Positive Clinical Study Results For Its Albuterol (Salbutamol) HFA Product 4/16/2015
RegeneRx JV Retains Ora, Inc. To Conduct Phase 3 Trial For NK And Phase 2b/3 Trial For Dry Eye Syndrome In U.S. 4/16/2015
AbbVie (ABBV)'s Investigational Chronic Hepatitis C Treatment Granted Priority Review In Japan 4/16/2015
TRANSGENE (ENX:TNG): Agreement With FDA Announced For Special Protocol Assessment For Upcoming Phase 3 Pexa-Vec Trial In Advanced Liver Cancer 4/16/2015
SillaJen Announces Agreement With The FDA For A Special Protocol Assessment For Upcoming Phase 3 Pexa-Vec Trial In Advanced Liver Cancer 4/16/2015
Provectus Biopharmaceuticals Inc. Opens Patient Enrollment; Begins Phase 3 International FDA Comparative Clinical Trial Of PV-10 For Melanoma 4/16/2015
Roche (RHHBY) Says 11 Late-Stage Cancer Drugs Will Enter Trials in 2015 4/15/2015
Pfizer (PFE) Announces Paloma-3 Trial For Ibrance® (Palbociclib) Stopped Early Due To Efficacy Seen In Patients With Hr+, Her2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy 4/15/2015
Ocular Therapeutix (OCUL) Stock Caves After Eye Pain Drug Flunks Pivotal Trial 4/15/2015
Heart Metabolics Limited And FDA Reach Agreement On Special Protocol Assessment For Single Phase 3 Trial Of Perhexiline In Hypertrophic Cardiomyopathy 4/15/2015
CytoTools: Recruitment Of Patients Now Complete For European Studies On Diabetic Foot (DFU) And Ulcus Cruris (VLU) Indications 4/15/2015
Oncobiologics Inc. Announces Completion Of Clinical Dosing For bevacizumab (Avastin biosimilar) Candidate 4/15/2015
Phase III Trial Of The Merck & Co. (MRK) And NewLink Genetics Investigational Ebola Vaccine Initiated In Sierra Leone 4/15/2015
Heart Metabolics And FDA Reach Agreement On Special Protocol Assessment For Single Phase 3 Trial Of Perhexiline In Hypertrophic Cardiomyopathy 4/15/2015
Soligenix (SNGX) Announces FDA Protocol Clearance Of Pivotal Phase 3 Clinical Trial Of SGX203 In Pediatric Crohn's Disease 4/14/2015
Catalyst Pharmaceuticals (CPRX) Announces Oral Presentation Of Firdapse Phase 3 Trial Data At American Academy of Neurology Annual Meeting (AAN) 4/14/2015
Bayer HealthCare (BAY) Devises Phase III Plans for Top Prospect 4/14/2015
DBV Tech Nabs FDA Breakthrough Status for Peanut Allergy Patch 4/13/2015
AEterna Zentaris (AEZS) Announces Plans To Initiate Phase 3 Study Of Macrilen In AGHD Following Successful Meeting With FDA 4/13/2015
Angionetics Initial Equity Funding To Advance As Independent Company To Develop And Commercialize Phase 3 Generx Gene Therapy Product Candidate 4/13/2015
Neothetics Initiates Pivotal Phase 3 Clinical Trials For LIPO-202, The First Non-Invasive Injectable Drug Candidate For Reduction Of Subcutaneous Abdominal Fat 4/13/2015
UK’s Aintree University Hospital Joins CEL-SCI (CVM)’s Phase III Head And Neck Cancer Trial 4/13/2015
Onxeo Announces 6th Positive DSMB Recommendation For Livatag Relive Study In HCC 4/13/2015
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Shows That Health-Related Quality-Of-Life Is Higher In ABSSSI Patients Deemed Cured Vs Improved After End Of Treatment 4/10/2015
Cesca Therapeutics Management Provides Update On Clinical Trials For Critical Limb Ischemia ("CLI") And Acute Myocardial Infarction ("AMI") 4/10/2015
Adamas Pharmaceuticals (ADMS) Receives Orphan Drug Designation For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia Associated With Parkinson's Disease 4/10/2015
Lipocine Inc. (LPCN) Announces Presentation Of Additional LPCN 1021 Clinical Data At American Society Of Andrology 40th Annual Conference 4/10/2015
Horizon Pharma (HZNP) Receives FDA Fast Track Designation For ACTIMMUNE In The Treatment Of Friedreich's Ataxia 4/10/2015
BioLife Solutions, Inc. (BLFS.OB) CryoStor Cell Preservation Media Embedded In Cardio3 BioSciences' Phase III Clinical Trials Of C-Cure Cell Therapy For Congestive Heart Failure 4/9/2015
Exelixis, Inc. (EXEL)’s Cabozantinib Granted Fast Track Designation By FDA For Advanced Renal Cell Carcinoma 4/9/2015